What is EVOTEC?
Evotec operates as a premier global platform company, specializing in the discovery and development of first-in-class and best-in-class pharmaceutical products. The firm distinguishes itself through a unique, technology-enabled approach that integrates proprietary research with extensive collaborative partnerships. By utilizing advanced data analytics and a diverse range of therapeutic modalities, Evotec effectively bridges the gap between early-stage scientific discovery and clinical-stage development. This operational model allows the company to maintain a competitive edge in the biotechnology industry, providing scalable solutions that accelerate the delivery of effective medical treatments to the global market.
How much funding has EVOTEC raised?
EVOTEC has raised a total of $772.9M across 8 funding rounds:
Stock Offering
$69.4M
Share Placement
$32.5M
Share Placement
$96.1M
Debt
$89.8M
Grant
$23.8M
Private Equity
$292.4M
Grant
$8.5M
Debt
$160.4M
Stock Issuance/Offering (1999): $69.4M, investors not publicly disclosed
Share Placement (2013): $32.5M led by Biotechnology Value Fund
Share Placement (2017): $96.1M supported by Novo A/S
Debt (2017): $89.8M featuring European Investment Bank
Grant (2019): $23.8M backed by Bill & Melinda Gates Foundation
Private Equity (2020): $292.4M with participation from Novo Holdings and Mubadala
Grant (2022): $8.5M led by German Federal Ministry of Education and Research
Debt (2023): $160.4M supported by European Investment Bank
Key Investors in EVOTEC
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
Bill & Melinda Gates Foundation
Established in 2000 and headquartered in Seattle, Washington, The Bill & Melinda Gates Foundation is an organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives.
Mubadala
Mubadala is a global investment company based in Abu Dhabi with a mandate to create sustainable financial returns and foster a diversified, globally integrated economy.
What's next for EVOTEC?
With the recent influx of capital, Evotec is well-positioned to accelerate its strategic growth initiatives and expand its research capabilities. The company is expected to focus on deepening its multimodality platform, enhancing its proprietary pipeline, and strengthening its collaborative research framework. As Evotec continues to navigate the complexities of the pharmaceutical landscape, this major enterprise-level funding provides the necessary liquidity to pursue long-term innovation, optimize operational efficiencies, and maintain its trajectory as a cornerstone of modern drug discovery. Future developments will likely center on scaling its technological infrastructure to meet the evolving demands of the global healthcare sector.
See full EVOTEC company page
